Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 22,369 matching trials from the live ClinicalTrials.gov search.
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
152
States / cities
Bakersfield, California • Duarte, California • Dublin, California + 119 more
Completed Phase 1Phase 2 Interventional Results available

Transdermal Basal Insulin Patch Study in Type 1 Diabetes

NCT00519623
Conditions
Type 1 Diabetes
Interventions
PassPort(R) Transdermal Insulin Delivery System
Other
Lead sponsor
Altea Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
387 Technology Circle, NW, Suite 100, Atlanta, Georgia
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
pomalidomide, bortezomib, dexamethasone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 1 more
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Conditions
Rheumatoid Arthritis
Interventions
Plant-based diet, Supplement
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
Interventions
Lenalidomide and Rituximab
Drug
Lead sponsor
Chronic Lymphocytic Leukemia Research Consortium
Network
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more
Conditions
Chronic Graft-Versus-Host-Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Asthma
Interventions
Coaching, providing social support
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cyclophosphamide, dexamethasone, lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Conditions
Rheumatoid Arthritis
Interventions
CFZ533, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Systemic Lupus Erythematosus
Interventions
Budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Allen, Texas • San Antonio, Texas
Conditions
Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions
SGN-CD19A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 3 more
Conditions
Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Leukapheresis
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational

Osteoporosis in Children With ALL

NCT00330538
Conditions
Leukemia, Lymphocytic, Acute, L1
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Not applicable Interventional Results available

Reducing Disparities in Medication Adherence in SLE

NCT03738826
Conditions
Systemic Lupus Erythematosus
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Conditions
Atopic Dermatitis
Interventions
Ivermectin Pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2030
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Venetoclax
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
West Hollywood, California • Omaha, Nebraska
Conditions
AL Amyloidosis, Amyloidosis
Interventions
non-interventional
Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
South San Francisco, California